Edition:
United States

Celsion Corp (CLSN.OQ)

CLSN.OQ on NASDAQ Stock Exchange Capital Market

0.24USD
4:00pm EDT
Change (% chg)

$-0.01 (-5.08%)
Prev Close
$0.25
Open
$0.25
Day's High
$0.25
Day's Low
$0.23
Volume
79,847
Avg. Vol
490,773
52-wk High
$1.60
52-wk Low
$0.19

CLSN.OQ

Chart for CLSN.OQ

About

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall... (more)

Overall

Beta: 1.44
Market Cap(Mil.): $14.14
Shares Outstanding(Mil.): 56.98
Dividend: --
Yield (%): --

Financials

  CLSN.OQ Industry Sector
P/E (TTM): -- 142.93 17.37
EPS (TTM): -0.85 -- --
ROI: -70.99 2.34 -5.89
ROE: -162.69 0.22 -5.30

BRIEF-Celsion Corp reports Q1 loss share per $0.12

* Celsion Corporation reports first quarter 2017 financial results and provides business update

May 12 2017

BRIEF-Celsion updates clinical data from the ovation study

* Celsion updates clinical data from the ovation study in newly diagnosed advanced ovarian cancer patients

May 04 2017

BRIEF-Celsion Corp files for stock shelf of up to $15 mln

* Celsion Corp files for stock shelf of up to $15 million - SEC filing Source text - http://bit.ly/2oHuVl7 Further company coverage:

Apr 25 2017

BRIEF-Celsion reports preclinical results of Thermodox for treatment of bladder cancer

* Celsion Corporation reports preclinical results of Thermodox® for the treatment of bladder cancer published in the international journal of hyperthermia

Apr 13 2017

BRIEF-Celsion Corp says selling stockholders may offer up to 5.1 mln shares of common stock - SEC Filing

* Celsion Corp - Selling stockholders may offer up to 5.1 million shares of common stock, issuable upon exercise of outstanding warrants - SEC Filing Source text: [http://bit.ly/2ncs2N9] Further company coverage:

Apr 05 2017

BRIEF-Celsion presents two posters on its GEN-1 IL-12 gene-mediated immunotherapy

* Celsion presents two posters on its GEN-1 IL-12 gene-mediated immunotherapy at the ASCO-SITC clinical immuno-oncology symposium

Feb 27 2017

BRIEF-Celsion Corp announces $5.0 mln public offering

* Celsion Corp - offering was priced at $0.23 per share of common stock

Feb 15 2017

More From Around the Web

Competitors

Earnings vs. Estimates